New combo aims to wipe out aggressive breast cancer before surgery
Disease control
Not yet recruiting
This study tests whether adding the drug inavolisib to standard targeted therapy and chemotherapy can eliminate more breast cancer before surgery in people with a specific genetic mutation (PIK3CA) and HER2-positive early breast cancer. About 164 participants will receive either …
Phase: PHASE2 • Sponsor: Zhimin Shao • Aim: Disease control
Last updated May 15, 2026 11:55 UTC